Molecular Characterization of human KRAS protein using Bioinformatics tools

Authors

  • Vinod P Sinoorkar  Walchand Centre for Biotechnology, Solapur, Maharashtra, India
  • Smita S Kashetti  Walchand Centre for Biotechnology, Solapur, Maharashtra, India
  • Akanksha S Degaonkar  Walchand Centre for Biotechnology, Solapur, Maharashtra, India
  • Vedika V Bhola  Walchand Centre for Biotechnology, Solapur, Maharashtra, India

Keywords:

Cancer, KRAS, Bioinformatics, Mutation, Molecular features

Abstract

Cancer is an abnormal growth of cells caused by multiple changes in gene expression leading to dysregulated balance of cell proliferation and cell death and ultimately evolving into a population of cells that can invade tissue and metastasize to distant sites , causing significant morbidity and if untreated death of host. Cancer develops due to genetic damage to DNA and epigenetic changes. These changes affect the normal functions of the cell, including cell proliferation, programmed cell death (apoptosis) and DNA repair. GTPase Kras also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog and Kras is a stable protein having length of about 189 a.a and molecular weight about 21655.83, in humans it is encoded by the KRAS gene. The protein product of the normal KRAS gene performs an essential function in normal tissue signalling, and the mutation of a KRAS gene is an essential step in the development of many cancers. Hence the present investigation was carried out to understand the molecular features of Kras protein by retrieving the protein sequence information from major protein database of bioinformatics.This analysis forms the base for the detailed understanding of molecular mechanism of Kras during onset of various cancers and further work on this, can pave a new dimension for the treatment of cancer.

References

  1. Yang, "Genetic susceptibility to lung cancer and co-morbidities "Journal of Thoracic Disease 2013.
  2. Herbst, “Lung cancer" New England Journal of medicine, 2008, 359.
  3. Alex A. Adjei, “K-ras as a Target for Lung Cancer Therapy”, Journal of Thoracic Oncology, June 2008 Vol. 3, No. 6, Supplement 2, S16 - S163.
  4. Jill E. Larsen and John D. Minna, “Molecular Biology of Lung Cancer: Clinical Implications”, Clin Chest Med, 2011, 703–740.
  5. Beatriz Stransky and Pedro Galante, “Application of Bioinformatics in Cancer Research”, Springer, 2009.
  6. Disuke kihara, “Bioinformatics research for cancer research with an emphasis on gene function and structure prediction tools”, Cancer informatics, 2007.
  7. Nishtha Singh, Sonal Upadhyay, et al , “In silico Analysis of Protein” J Bioinform, Genomics, Proteomics, 07 September 2016,1-7.
  8. Anshul Tiwari, Monika Sharma, et al, “In silico Characterization of Retinal S-antigen and Retinol Binding Protein-3: Target against Eales’ Disease”Int.J. Bioautomation, 2014, 18(4), 287-296.
  9. Razumilava, “Classification, diagnosis and management of cholangio carcinoma”, 2013.
  10. Kranenburg O “The KRAS oncogenes: past, present and future, 2005. 
  11. Merck Manual Professional Edition, "Lung Carcinoma: Tumors of the Lungs", Online edition, Retrieved 15 August 2007.
  12. Jakopovic, et al; "Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy", 2013.
  13. D Behera, “Lung Cancer in India NewDelhi”, 2008.

Downloads

Published

2018-04-30

Issue

Section

Research Articles

How to Cite

[1]
Vinod P Sinoorkar, Smita S Kashetti, Akanksha S Degaonkar, Vedika V Bhola, " Molecular Characterization of human KRAS protein using Bioinformatics tools, International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011, Volume 4, Issue 5, pp.1093-1098, March-April-2018.